LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S.

The country's immigrant population may have dropped by roughly 2 million people in the first six months of the year, according to new government data. The new data offer an early – if imperfect – ...

Rusfertide effectively maintains hematocrit control and reduces phlebotomy need in PV patients, as shown in the VERIFY study over 52 weeks. The therapy, a hepcidin mimetic peptide, regulates iron ...